FTH
Faeth TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The $200 million private placement and $202.8 million of cash, cash equivalents, and marketable securities as of March 31, 2026 provide funding to advance PIKTOR through endometrial and breast-cancer milestones. [#SEC-8K-2026-05-15]
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.5.
What can break
Binary clinical efficacy or tolerability disappointment in the Phase 2 endometrial-cancer program.
Momentum
99
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $50.00 · Bear $17.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $53.83
Why
Momentum99 · Δ7d +0.5
Value41 · Δ7d +0.1
Sentiment53 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
53
34% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.8 / Value 41.1 / Sentiment 53.3
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$726.7M
Beta
0.28
Shares Out
25.78M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.49
Rev YoY
-
EPS YoY
+2312.3%
Gross Margin
-
Op Margin
-
Net Debt
-$19.68M
Current Ratio
14.39
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology